Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas
Latest Information Update: 08 Jan 2025
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 06 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 11 Sep 2025.
- 06 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2024 Planned primary completion date changed from 20 Feb 2024 to 31 Dec 2024.